FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Arch Virol Suppl / Recombinant canarypoxvirus vaccine carrying the prM/E genes ...
Archives of virology. Supplementum2004; (18); 221-230; doi: 10.1007/978-3-7091-0572-6_20

Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.

Abstract: An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-vaccinated controls. Individual sera were taken periodically and tested for neutralising antibodies against WNV. Horses were challenged by allowing WNV-infected Aedes albopictus mosquitoes to feed on them two weeks (second trial) or one year (first trial) after the second vaccination. After challenge, horses were monitored for clinical signs of disease, and blood samples were collected for detection of WNV viremia and antibody. In both trials, all vaccinated horses developed neutralising antibodies against WNV. None of the vaccinated or control horses developed clinical signs of WNV disease upon challenge. None of the nine horses challenged 2 weeks after primary vaccination and only one of the ten vaccinated horses challenged 1 year after vaccination developed detectable viremia after challenge, whereas more than 80% of the controls became infected. Results from these studies demonstrated that a primary course of two doses of vCP2017 provides both antibody response and an early immunity in horses against WNV viremia.
Get Full Text
Publication Date: 2004-05-04 PubMed ID: 15119777DOI: 10.1007/978-3-7091-0572-6_20Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper explores the creation and efficacy of a recombinant canarypoxvirus vaccine, named vCP2017, which carries two genes from a 1999 New York isolate of West Nile virus (WNV). When administered to horses, the vaccine was shown to elicit an immune response, reducing the risk of WNV infection considerably.

Creation of the vCP2017 Vaccine

  • The researchers constructed the vaccine using ALVAC, a type of canarypoxvirus.
  • From a 1999 New York-isolated strain of West Nile virus, the prM and E genes were taken and used to create the recombinant vaccine vCP2017.

Assessment of the vCP2017 Vaccine

  • Two experiments were conducted to evaluate the vaccine’s protective efficacy in horses.
  • The first experiment was a dose titration study examining serum neutralising antibody responses and duration of immunity against WNV.
  • The second experiment assessed the onset of protection.
  • A total of 28 adult horses received two doses of the vaccine via intramuscular injections at 5-week intervals, while 16 horses were kept as non-vaccinated controls for comparison.

Immunological Response to the vCP2017 Vaccine

  • Horses were periodically tested for neutralising antibodies against WNV, results showing that all vaccinated horses had developed such antibodies.
  • The horses were later exposed to WNV-infected mosquitoes, then monitored for clinical signs of disease, WNV viremia, and the presence of antibodies.
  • Judging by these observations, neither vaccinated nor control horses displayed any clinical symptoms of WNV.
  • Upon examination two weeks after primary vaccination, none of the nine vaccinated horses challenged showed detectable viremia; even one year following vaccination, only one out of ten vaccinated horses showed signs of viremia, compared to over 80% of the control group.

Conclusion

  • The results conclusively demonstrated that a primary course of two doses of vCP2017 can provide an early immune response in horses against WNV viremia, as well as an antibody response; indicating a promising tool for WNV prevention.

Cite This Article

APA
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B. (2004). Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl(18), 221-230. https://doi.org/10.1007/978-3-7091-0572-6_20

Publication

Archives of virology. Supplementum
ISSN: 0939-1983
NlmUniqueID: 9214275
Country: Austria
Language: English
Issue: 18
Pages: 221-230

Researcher Affiliations

Minke, J M
  • Merial SAS, Lyon, France. julius.minke@merial.com
Siger, L
    Karaca, K
      Austgen, L
        Gordy, P
          Bowen, R
            Renshaw, R W
              Loosmore, S
                Audonnet, J C
                  Nordgren, B

                    MeSH Terms

                    • Animals
                    • Base Sequence
                    • Canarypox virus / immunology
                    • Cloning, Molecular
                    • Culicidae / virology
                    • DNA Primers
                    • Horse Diseases / immunology
                    • Horse Diseases / virology
                    • Horses / immunology
                    • Male
                    • Plasmids / genetics
                    • Polymerase Chain Reaction / methods
                    • Vaccines, Attenuated / therapeutic use
                    • Vaccines, Synthetic / therapeutic use
                    • Viral Plaque Assay
                    • Viral Vaccines / therapeutic use
                    • West Nile Fever / immunology
                    • West Nile Fever / veterinary
                    • West Nile virus / immunology
                    • West Nile virus / isolation & purification

                    Citations

                    This article has been cited 37 times.
                    1. van Bree JWM, Visser I, Duyvestyn JM, Aguilar-Bretones M, Marshall EM, van Hemert MJ, Pijlman GP, van Nierop GP, Kikkert M, Rockx BHG, Miesen P, Fros JJ. Novel approaches for the rapid development of rationally designed arbovirus vaccines.. One Health 2023 Jun;16:100565.
                      doi: 10.1016/j.onehlt.2023.100565pubmed: 37363258google scholar: lookup
                    2. Wu B, Qi Z, Qian X. Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development.. Viruses 2023 Mar 23;15(4).
                      doi: 10.3390/v15040813pubmed: 37112794google scholar: lookup
                    3. Sun H, Acharya D, Paul AM, Lai H, He J, Bai F, Chen Q. Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus.. Vaccines (Basel) 2023 Jan 17;11(2).
                      doi: 10.3390/vaccines11020197pubmed: 36851075google scholar: lookup
                    4. Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.. Front Vet Sci 2021;8:654289.
                      doi: 10.3389/fvets.2021.654289pubmed: 33937377google scholar: lookup
                    5. Nebbak A, Monteil-Bouchard S, Berenger JM, Almeras L, Parola P, Desnues C. Virome Diversity among Mosquito Populations in a Sub-Urban Region of Marseille, France.. Viruses 2021 Apr 27;13(5).
                      doi: 10.3390/v13050768pubmed: 33925487google scholar: lookup
                    6. Arfuso F, Giudice E, Di Pietro S, Piccione G, Giannetto C. Modulation of Serum Protein Electrophoretic Pattern and Leukocyte Population in Horses Vaccinated against West Nile Virus.. Animals (Basel) 2021 Feb 11;11(2).
                      doi: 10.3390/ani11020477pubmed: 33670395google scholar: lookup
                    7. Jiménez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Moreno S, Nogales A, Ortego J, Marín-López A. Viral Vector Vaccines against Bluetongue Virus.. Microorganisms 2020 Dec 25;9(1).
                      doi: 10.3390/microorganisms9010042pubmed: 33375723google scholar: lookup
                    8. Habarugira G, Suen WW, Hobson-Peters J, Hall RA, Bielefeldt-Ohmann H. West Nile Virus: An Update on Pathobiology, Epidemiology, Diagnostics, Control and "One Health" Implications.. Pathogens 2020 Jul 19;9(7).
                      doi: 10.3390/pathogens9070589pubmed: 32707644google scholar: lookup
                    9. Lecollinet S, Pronost S, Coulpier M, Beck C, Gonzalez G, Leblond A, Tritz P. Viral Equine Encephalitis, a Growing Threat to the Horse Population in Europe?. Viruses 2019 Dec 24;12(1).
                      doi: 10.3390/v12010023pubmed: 31878129google scholar: lookup
                    10. Lai H, Paul AM, Sun H, He J, Yang M, Bai F, Chen Q. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.. Vaccine 2018 Mar 27;36(14):1846-1852.
                      doi: 10.1016/j.vaccine.2018.02.073pubmed: 29490880google scholar: lookup
                    11. Wang J, Yang J, Ge J, Hua R, Liu R, Li X, Wang X, Shao Y, Sun E, Wu D, Qin C, Wen Z, Bu Z. Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry.. Virol J 2016 Jun 24;13:109.
                      doi: 10.1186/s12985-016-0568-5pubmed: 27342050google scholar: lookup
                    12. Acharya D, Bai F. An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.. Methods Mol Biol 2016;1435:249-91.
                      doi: 10.1007/978-1-4939-3670-0_19pubmed: 27188563google scholar: lookup
                    13. Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines.. Viruses 2015 Apr 7;7(4):1726-803.
                      doi: 10.3390/v7041726pubmed: 25853483google scholar: lookup
                    14. Angenvoort J, Brault AC, Bowen RA, Groschup MH. West Nile viral infection of equids.. Vet Microbiol 2013 Nov 29;167(1-2):168-80.
                      doi: 10.1016/j.vetmic.2013.08.013pubmed: 24035480google scholar: lookup
                    15. Iyer AV, Kousoulas KG. A review of vaccine approaches for West Nile virus.. Int J Environ Res Public Health 2013 Sep 10;10(9):4200-23.
                      doi: 10.3390/ijerph10094200pubmed: 24025396google scholar: lookup
                    16. Wheeler SS, Langevin S, Woods L, Carroll BD, Vickers W, Morrison SA, Chang GJ, Reisen WK, Boyce WM. Efficacy of three vaccines in protecting Western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (Aphelocoma insularis).. Vector Borne Zoonotic Dis 2011 Aug;11(8):1069-80.
                      doi: 10.1089/vbz.2010.0173pubmed: 21438693google scholar: lookup
                    17. Weli SC, Tryland M. Avipoxviruses: infection biology and their use as vaccine vectors.. Virol J 2011 Feb 3;8:49.
                      doi: 10.1186/1743-422X-8-49pubmed: 21291547google scholar: lookup
                    18. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.. J Infect Dis 2011 Jan 1;203(1):75-84.
                      doi: 10.1093/infdis/jiq003pubmed: 21148499google scholar: lookup
                    19. Demento SL, Bonafé N, Cui W, Kaech SM, Caplan MJ, Fikrig E, Ledizet M, Fahmy TM. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.. J Immunol 2010 Sep 1;185(5):2989-97.
                      doi: 10.4049/jimmunol.1000768pubmed: 20660705google scholar: lookup
                    20. Widman DG, Ishikawa T, Giavedoni LD, Hodara VL, Garza Mde L, Montalbo JA, Travassos Da Rosa AP, Tesh RB, Patterson JL, Carrion R Jr, Bourne N, Mason PW. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.. Am J Trop Med Hyg 2010 Jun;82(6):1160-7.
                      doi: 10.4269/ajtmh.2010.09-0310pubmed: 20519618google scholar: lookup
                    21. Rossi SL, Ross TM, Evans JD. West Nile virus.. Clin Lab Med 2010 Mar;30(1):47-65.
                      doi: 10.1016/j.cll.2009.10.006pubmed: 20513541google scholar: lookup
                    22. Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R Jr, de la Garza M, Coller BA, Clements D, Ogata S, Wong T, Martyak T, Weeks-Levy C. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.. Clin Vaccine Immunol 2009 Sep;16(9):1332-7.
                      doi: 10.1128/CVI.00119-09pubmed: 19641099google scholar: lookup
                    23. Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, Baghian A, Apetrei C, Marx PA, Kousoulas KG. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.. Vaccine 2009 Feb 5;27(6):893-903.
                      doi: 10.1016/j.vaccine.2008.11.087pubmed: 19070640google scholar: lookup
                    24. Siirin MT, Travassos da Rosa AP, Newman P, Weeks-Levy C, Coller BA, Xiao SY, Lieberman MM, Watts DM. Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters.. Am J Trop Med Hyg 2008 Dec;79(6):955-62.
                      pubmed: 19052311
                    25. Zhang B, Dong H, Stein DA, Shi PY. Co-selection of West Nile virus nucleotides that confer resistance to an antisense oligomer while maintaining long-distance RNA/RNA base pairings.. Virology 2008 Dec 5;382(1):98-106.
                      doi: 10.1016/j.virol.2008.08.044pubmed: 18842280google scholar: lookup
                    26. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, Keil GM, Klonjkowski B, Le Potier MF, Libeau G, Ortego J, Richardson J, Takamatsu HH. Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.. Vaccine 2008 Dec 2;26(51):6508-28.
                      doi: 10.1016/j.vaccine.2008.09.044pubmed: 18838097google scholar: lookup
                    27. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.. J Infect Dis 2007 Dec 15;196(12):1732-40.
                      doi: 10.1086/523650pubmed: 18190252google scholar: lookup
                    28. Childs JE. Pre-spillover prevention of emerging zoonotic diseases: what are the targets and what are the tools?. Curr Top Microbiol Immunol 2007;315:389-443.
                      doi: 10.1007/978-3-540-70962-6_16pubmed: 17848073google scholar: lookup
                    29. Seino KK, Long MT, Gibbs EP, Bowen RA, Beachboard SE, Humphrey PP, Dixon MA, Bourgeois MA. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.. Clin Vaccine Immunol 2007 Nov;14(11):1465-71.
                      doi: 10.1128/CVI.00249-07pubmed: 17687109google scholar: lookup
                    30. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.. J Virol 2007 Oct;81(19):10329-39.
                      doi: 10.1128/JVI.00512-07pubmed: 17652394google scholar: lookup
                    31. Choi KS, Ko YJ, Nah JJ, Kim YJ, Kang SY, Yoon KJ, Joo YS. Monoclonal antibody-based competitive enzyme-linked immunosorbent assay for detecting and quantifying West Nile virus-neutralizing antibodies in horse sera.. Clin Vaccine Immunol 2007 Feb;14(2):134-8.
                      doi: 10.1128/CVI.00322-06pubmed: 17135450google scholar: lookup
                    32. Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa A, Humphreys T, Weeks-Levy C. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.. Vaccine 2007 Jan 5;25(3):414-23.
                      doi: 10.1016/j.vaccine.2006.08.018pubmed: 16996661google scholar: lookup
                    33. Debiasi RL, Tyler KL. West Nile virus meningoencephalitis.. Nat Clin Pract Neurol 2006 May;2(5):264-75.
                      doi: 10.1038/ncpneuro0176pubmed: 16932563google scholar: lookup
                    34. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge.. J Virol 2006 Aug;80(16):7929-38.
                      doi: 10.1128/JVI.00263-06pubmed: 16873250google scholar: lookup
                    35. Mason PW, Shustov AV, Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication.. Virology 2006 Aug 1;351(2):432-43.
                      doi: 10.1016/j.virol.2006.04.003pubmed: 16712897google scholar: lookup
                    36. Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P. A live, attenuated recombinant West Nile virus vaccine.. Proc Natl Acad Sci U S A 2006 Apr 25;103(17):6694-9.
                      doi: 10.1073/pnas.0601932103pubmed: 16617103google scholar: lookup
                    37. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease.. Emerg Infect Dis 2005 Aug;11(8):1174-9.
                      doi: 10.3201/eid1108.050289bpubmed: 16102303google scholar: lookup
                    Subscribe to our newsletter
                    Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.